Epidermolysis bullosa: Advances in research and treatment
Prodinger C., Reichelt J., Bauer JW., Laimer M.
Narrative Review on Chronic Wound, published in Exp Dermatol (2019) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Exp Dermatol (2019)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 31140655
- PMCID
- PMC6900197
- DOI
- 10.1111/exd.13979
- Citations
- 60
Abstract (original English)
Epidermolysis bullosa (EB) is the umbrella term for a group of rare inherited skin fragility disorders caused by mutations in at least 20 different genes. There is no cure for any of the subtypes of EB resulting from different mutations, and current therapy only focuses on the management of wounds and pain. Novel effective therapeutic approaches are therefore urgently required. Strategies include gene-, protein- and cell-based therapies. This review discusses molecular procedures currently under investigation at the EB House Austria, a designated Centre of Expertise implemented in the European Reference Network for Rare and Undiagnosed Skin Diseases. Current clinical research activities at the EB House Austria include newly developed candidate substances that have emerged out of our translational research initiatives as well as already commercially available medications that are applied in off-licensed indications. Squamous cell carcinoma is the major cause of death in severe forms of EB. We are evaluating immunotherapy using an anti-PD1 monoclonal antibody as a palliative treatment option for locally advanced or metastatic squamous cell carcinoma of the skin unresponsive to previous systemic therapy. In addition, we are evaluating topical calcipotriol and topical diacerein as potential agents to improve the healing of skin wounds in EBS patients. Finally, the review will highl
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Efficacy and Safety of Fat Graft Myringoplasty Combined With Platelet-Rich Plasma for Managing Chronic Tympanic Membrane Perforations: A Systematic Review and Meta-Analysis
Meta-analysis with a reported sample of 522 on Chronic Wound, published in Clin Exp Otorhinolaryngol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 522
Clin Exp Otorhinolaryngol1 citations - Level ASystematic ReviewEurope PMC
Stem cell-derived exosomes in tissue regeneration of oral and maxillofacial region: A systematic review
Systematic Review on Chronic Wound, published in Medicine (Baltimore) (2026) — summary generated from the PubMed abstract.
- 2026
Medicine (Baltimore) - Level ASystematic ReviewEurope PMC
Best evidence summary for platelet-rich plasma treatment of chronic wounds
Systematic Review on Chronic Wound, published in Regen Ther (2026) — summary generated from the PubMed abstract.
- 2026
Regen Ther - Level ASystematic ReviewEurope PMC
Dedifferentiation of Mature Adipocytes and Their Future Potential for Regenerative Medicine Applications
Systematic Review on Type 2 Diabetes, Chronic Wound, published in Biomedicines (2026) — summary generated from the PubMed abstract.
- 2026
Biomedicines - Level AMeta-analysisEurope PMC
Effect of stem cell therapies on tendon-bone healing after anterior cruciate ligament reconstruction in animal models: Protocol for a systematic review and meta-analysis
Meta-analysis on Tendon Injury, Ligament Injury, Chronic Wound, published in PLoS One (2026) — summary generated from the PubMed abstract.
- 2026
PLoS One1 citations - Level AMeta-analysisEurope PMC
Therapeutic value of mesenchymal stem cell-derived extracellular vesicles in hypertrophic and keloid scars: a systematic review and meta-analysis
Meta-analysis on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
Front Cell Dev Biol